Hyaluronan and N-ERC/Mesothelin as Key Biomarkers in a Specific Two-Step Model to Predict Pleural Malignant Mesothelioma

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Mundt, Filip ^a   Nilsonne, Gustav ^a,b   Arslan, Sertaç ^c   Csürös, Karola ^a   Hillerdal, Gunnar ^d   Yildirim, Huseyin ^c   Metintas, Muzaffer ^c   Dobra, Katalin ^a   Hjerpe, Anders ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b STOCKHOLM UNIVERSITY   (Sweden)

^c OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^d KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; HYALURONIC ACID; MESOTHELIN; OSTEOPONTIN; SYNDECAN 1; SYNDECAN 2; THIOREDOXIN;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PLEURA EFFUSION; PLEURA MESOTHELIOMA; PREDICTION; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; TEST RETEST RELIABILITY; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; BLOTTING, WESTERN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GPI-LINKED PROTEINS; HUMANS; HYALURONIC ACID; LOGISTIC MODELS; MALE; MESOTHELIOMA; MIDDLE AGED; MODELS, BIOLOGICAL; OSTEOPONTIN; PLEURAL EFFUSION; PLEURAL EFFUSION, MALIGNANT; PROSPECTIVE STUDIES; ROC CURVE; SYNDECAN-1; SYNDECAN-2; THIOREDOXINS; TUMOR MARKERS, BIOLOGICAL;

EID: 84882682295     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072030     Document Type: Article

References (54)

1. Sterman DH, Albelda SM, (2005) Advances in the diagnosis, evaluation, and management of malignant pleural mesothelioma. Respirology 10: 266-283.
2. Dejmek A, Hjerpe A, (2005) The combination of CEA, EMA, and BerEp4 and hyaluronan analysis specifically identifies 79% of all histologically verified mesotheliomas causing an effusion. Diagn Cytopathol 32: 160-166.
3. Flores-Staino C, Darai-Ramqvist E, Dobra K, Hjerpe A, (2010) Adaptation of a commercial fluorescent in situ hybridization test to the diagnosis of malignant cells in effusions. Lung Cancer 68: 39-43.
4. Segal A, Sterrett GF, Frost FA, Shilkin KB, Olsen NJ, et al. (2013) A diagnosis of malignant pleural mesothelioma can be made by effusion cytology: results of a 20 year audit. Pathology 45: 44-48.
5. Hellstrom I, Raycraft J, Kanan S, Sardesai NY, Verch T, et al. (2006) Mesothelin variant 1 is released from tumor cells as a diagnostic marker. Cancer Epidemiol Biomarkers Prev 15: 1014-1020.
6. Shiomi K, Miyamoto H, Segawa T, Hagiwara Y, Ota A, et al. (2006) Novel ELISA system for detection of N-ERC/mesothelin in the sera of mesothelioma patients. Cancer Sci 97: 928-932.
7. Scherpereel A, Grigoriu B, Conti M, Gey T, Gregoire M, et al. (2006) Soluble mesothelin-related peptides in the diagnosis of malignant pleural mesothelioma. Am J Respir Crit Care Med 173: 1155-1160.
8. Robinson BW, Creaney J, Lake R, Nowak A, Musk AW, et al. (2003) Mesothelin-family proteins and diagnosis of mesothelioma. Lancet 362: 1612-1616.
9. Grigoriu B, Chahine B, Zerimech F, Gregoire M, Balduyck M, et al. (2009) Serum mesothelin has a higher diagnostic utility than hyaluronic acid in malignant mesothelioma. Clin Biochem 42: 1046-1050.
10. Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, et al. (2011) Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma-which is best? Lung Cancer 74: 55-60.
11. Nurminen M, Dejmek A, Martensson G, Thylen A, Hjerpe A, (1994) Clinical utility of liquid-chromatographic analysis of effusions for hyaluronate content. Clin Chem 40: 777-780.
12. Frebourg T, Lerebours G, Delpech B, Benhamou D, Bertrand P, et al. (1987) Serum hyaluronate in malignant pleural mesothelioma. Cancer 59: 2104-2107.
13. Pettersson T, Froseth B, Riska H, Klockars M, (1988) Concentration of hyaluronic acid in pleural fluid as a diagnostic aid for malignant mesothelioma. Chest 94: 1037-1039.
14. Thylen A, Hjerpe A, Martensson G, (2001) Hyaluronan content in pleural fluid as a prognostic factor in patients with malignant pleural mesothelioma. Cancer 92: 1224-1230.
15. Pass HI, Lott D, Lonardo F, Harbut M, Liu Z, et al. (2005) Asbestos exposure, pleural mesothelioma, and serum osteopontin levels. N Engl J Med 353: 1564-1573.
16. Grigoriu BD, Scherpereel A, Devos P, Chahine B, Letourneux M, et al. (2007) Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment. Clin Cancer Res 13: 2928-2935.
17. Cappia S, Righi L, Mirabelli D, Ceppi P, Bacillo E, et al. (2008) Prognostic role of osteopontin expression in malignant pleural mesothelioma. Am J Clin Pathol 130: 58-64.
18. Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, et al. (2008) Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma. J Thorac Oncol 3: 851-857.
19. Fedarko NS, Jain A, Karadag A, Van Eman MR, Fisher LW, (2001) Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer. Clin Cancer Res 7: 4060-4066.
20. Sun X, Dobra K, Bjornstedt M, Hjerpe A, (2000) Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. Differentiation 66: 181-188.
21. Kahlos K, Soini Y, Saily M, Koistinen P, Kakko S, et al. (2001) Up-regulation of thioredoxin and thioredoxin reductase in human malignant pleural mesothelioma. Int J Cancer 95: 198-204.
22. Rihn BH, Mohr S, McDowell SA, Binet S, Loubinoux J, et al. (2000) Differential gene expression in mesothelioma. FEBS Lett 480: 95-100.
23. Mohr S, Bottin MC, Lannes B, Neuville A, Bellocq JP, et al. (2004) Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. Biochimie 86: 13-19.
24. Gulyas M, Hjerpe A, (2003) Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium. J Pathol 199: 479-487.
25. Saqi A, Yun SS, Yu GH, Alexis D, Taub RN, et al. (2005) Utility of CD138 (syndecan-1) in distinguishing carcinomas from mesotheliomas. Diagn Cytopathol 33: 65-70.
26. Scherpereel A, Astoul P, Baas P, Berghmans T, Clayson H, et al. (2010) Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma. Eur Respir J 35: 479-495.
27. Seidel C, Gulyas M, David G, Dobra K, Theocharis AD, et al. (2004) A sandwich ELISA for the estimation of human syndecan-2 and syndecan-4 in biological samples. J Pharm Biomed Anal 34: 797-801.
28. David G, van der Schueren B, Marynen P, Cassiman JJ, van den Berghe H, (1992) Molecular cloning of amphiglycan, a novel integral membrane heparan sulfate proteoglycan expressed by epithelial and fibroblastic cells. J Cell Biol 118: 961-969.
29. Hjerpe A, (1986) Liquid-chromatographic determination of hyaluronic acid in pleural and ascitic fluids. Clin Chem 32: 952-956.
30. Spiegelhalter DJ, (1986) Probabilistic prediction in patient management and clinical trials. Stat Med 5: 421-433.
31. Pencina MJ, D'Agostino RB Sr, D'Agostino RB Jr, Vasan RS (2008) Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med 27: 157-172; discussion 207-112.
32. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, et al. (2010) Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology 21: 128-138.
33. Team RDC (2011) R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria ISBN 3-900051-07-0.
34. Rizopoulos D. bootStepAIC: Bootstrap stepAIC. R package version 1.2-0.
35. Monica L-R, Maria XR-A (2012) OptimalCutpoints: Computing optimal cutpoints in diagnostic tests. R package version 1.0.
36. Harrell FE. rms: Regression Modeling Strategies. R package version 3.4-0.
37. Welker L, Muller M, Holz O, Vollmer E, Magnussen H, et al. (2007) Cytological diagnosis of malignant mesothelioma-improvement by additional analysis of hyaluronic acid in pleural effusions. Virchows Arch 450: 455-461.
38. Martensson G, Thylen A, Lindquist U, Hjerpe A, (1994) The sensitivity of hyaluronan analysis of pleural fluid from patients with malignant mesothelioma and a comparison of different methods. Cancer 73: 1406-1410.
39. Yamada S, Tabata C, Tabata R, Fukuoka K, Nakano T (2011) Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma. Clin Chem Lab Med.
40. Davies HE, Sadler RS, Bielsa S, Maskell NA, Rahman NM, et al. (2009) Clinical impact and reliability of pleural fluid mesothelin in undiagnosed pleural effusions. Am J Respir Crit Care Med 180: 437-444.
41. Aleman C, Manuel Porcel J, Ma Segura R, Alegre J, Esquerda A, et al. (2009) Pleural fluid mesothelin for the differential diagnosis of exudative pleural effusions. Med Clin (Barc) 133: 449-453.
42. Pass HI, Wali A, Tang N, Ivanova A, Ivanov S, et al. (2008) Soluble mesothelin-related peptide level elevation in mesothelioma serum and pleural effusions. Ann Thorac Surg 85: 265-272; discussion 272.
43. Creaney J, Yeoman D, Naumoff LK, Hof M, Segal A, et al. (2007) Soluble mesothelin in effusions: a useful tool for the diagnosis of malignant mesothelioma. Thorax 62: 569-576.
44. Moschos C, Porfiridis I, Psallidas I, Kollintza A, Stathopoulos GT, et al. (2009) Osteopontin is upregulated in malignant and inflammatory pleural effusions. Respirology 14: 716-722.
45. Iwahori K, Osaki T, Serada S, Fujimoto M, Suzuki H, et al. (2008) Megakaryocyte potentiating factor as a tumor marker of malignant pleural mesothelioma: evaluation in comparison with mesothelin. Lung Cancer 62: 45-54.
46. Hollevoet K, Nackaerts K, Thimpont J, Germonpre P, Bosquee L, et al. (2010) Diagnostic performance of soluble mesothelin and megakaryocyte potentiating factor in mesothelioma. Am J Respir Crit Care Med 181: 620-625.
47. Pantazopoulos I, Boura P, Xanthos T, Syrigos K, (2013) Effectiveness of mesothelin family proteins and osteopontin for malignant mesothelioma. Eur Respir J 41: 706-715.
48. Hollevoet K, Nackaerts K, Gosselin R, De Wever W, Bosquee L, et al. (2011) Soluble mesothelin, megakaryocyte potentiating factor, and osteopontin as markers of patient response and outcome in mesothelioma. J Thorac Oncol 6: 1930-1937.
49. Kao SC, Reid G, van Zandwijk N, Henderson DW, Klebe S, (2011) Molecular biomarkers in malignant mesothelioma: state of the art. Pathology 43: 201-212.
50. Ivanov SV, Ivanova AV, Goparaju CM, Chen Y, Beck A, et al. (2009) Tumorigenic properties of alternative osteopontin isoforms in mesothelioma. Biochem Biophys Res Commun 382: 514-518.
51. Vordermark D, Said HM, Katzer A, Kuhnt T, Hansgen G, et al. (2006) Plasma osteopontin levels in patients with head and neck cancer and cervix cancer are critically dependent on the choice of ELISA system. BMC Cancer 6: 207.
52. Tabata C, Tabata R, Nakano T (2011) Is serum thioredoxin-1 a useful clinical marker for malignant pleural mesothelioma? Antioxid Redox Signal.
53. Ostroff RM, Mehan MR, Stewart A, Ayers D, Brody EN, et al. (2012) Early detection of malignant pleural mesothelioma in asbestos-exposed individuals with a noninvasive proteomics-based surveillance tool. PLoS One 7: e46091.
54. Metintas M, Hillerdal G, Metintas S, Dumortier P, (2010) Endemic malignant mesothelioma: exposure to erionite is more important than genetic factors. Arch Environ Occup Health 65: 86-93.